The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Cyclooxygenase (COX)-2 Inhibitor Celecoxib Abrogates TNF-Induced NF-κB Activation through Inhibition of Activation of IκBα Kinase and Akt in Human Non-Small Cell Lung Carcinoma: Correlation with Suppression of COX-2 Synthesis
Abstract
The cyclooxygenase 2 (COX-2) inhibitor celecoxib (also called celebrex), approved for the treatment of colon carcinogenesis, rheumatoid arthritis, and other inflammatory diseases, has been shown to induce apoptosis and inhibit angiogenesis. Because NF-κB plays a major role in regulation of apoptosis, angiogenesis, carcinogenesis, and inflammation, we postulated that celecoxib modulates NF-κB. In the present study, we investigated the effect of this drug on the activation of NF-κB by a wide variety of agents. We found that celecoxib suppressed NF-κB activation induced by various carcinogens, including TNF, phorbol ester, okadaic acid, LPS, and IL-1β. Celecoxib inhibited TNF-induced IκBα kinase activation, leading to suppression of IκBα phosphorylation and degradation. Celecoxib suppressed both inducible and constitutive NF-κB without cell type specificity. Celecoxib also suppressed p65 phosphorylation and nuclear translocation. Akt activation, which is required for TNF-induced NF-κB activation, was also suppressed by this drug. Celecoxib also inhibited the TNF-induced interaction of Akt with IκBα kinase (IKK). Celecoxib abrogated the NF-κB-dependent reporter gene expression activated by TNF, TNF receptor, TNF receptor-associated death domain, TNF receptor-associated factor 2, NF-κB-inducing kinase, and IKK, but not that activated by p65. The COX-2 promoter, which is regulated by NF-κB, was also inhibited by celecoxib, and this inhibition correlated with suppression of TNF-induced COX-2 expression. Besides NF-κB, celecoxib also suppressed TNF-induced JNK, p38 MAPK, and ERK activation. Thus, overall, our results indicate that celecoxib inhibits NF-κB activation through inhibition of IKK and Akt activation, leading to down-regulation of synthesis of COX-2 and other genes needed for inflammation, proliferation, and carcinogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activators and target genes of Rel/NF-κB transcription factors
Pahl, H. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203239 · Cited by 3,727
Missing Pieces in the NF-κB Puzzle
Ghosh, S., & Karin, M. (2002) · Cell · doi:10.1016/s0092-8674(02)00703-1 · Cited by 3,638
Yamamoto, K., Arakawa, T., Ueda, N., & Yamamoto, S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.52.31315 · Cited by 647 · cited 1×
“Although celecoxib is known to inhibit the activity of COX-2, our results indicate that it can also suppress the synthesis of COX-2, which is regulated by NF- B (48).”
Background
Cited by
Inflammation: Gearing the journey to cancer
KUNDU, J., & SURH, Y. (2008) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2008.03.002 · Cited by 803
Nuclear factor-κB inhibitors as sensitizers to anticancer drugs
Nakanishi, C., & Toi, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1588 · Cited by 724
Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression
Bassères, D. S., & Baldwin, A. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209942 · Cited by 667
NF-κB and IKK as therapeutic targets in cancer
Kim, H. J., Hawke, N., & Baldwin, A. S. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401877 · Cited by 391
Veltman, J. D., Lambers, M. E., van Nimwegen, M., Hendriks, R. W., Hoogsteden, H. C., Aerts, J. G., & Hegmans, J. P. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-464 · Cited by 291
Metadata
- Authors
- Shishodia, S., Koul, D., & Aggarwal, B. B.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-08-01
- Volume
- 173
- Issue
- 3
- Pages
- 2011-2022
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1522455546
- Cited by
- 185
- References
- 3
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.